Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
wharton's jelly-derived mesenchymal stem cells
- Development stage
- Phase 2
- Lead developer
- Beike Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
WJ-MSC cells (Wharton's Jelly-derived Mesenchymal Stem Cells) are an allogeneic, cell-based biologic therapy derived from the Wharton's jelly of the human umbilical cord matrix. These cells are of epiblastic origin and express both human embryonic stem cell (hESC) and mesenchymal stem cell markers. In the context of ST-segment elevation myocardial infarction (STEMI), WJ-MSCs are administered intravenously to reduce microvascular obstruction and hemorrhage following ischemia-reperfusion injury. The cells are believed to exert their therapeutic effects through integration into ischemic cardiac tissue and the secretion of paracrine factors that provide anti-inflammatory and regenerative signals. They are considered advantageous over autologous bone marrow-derived MSCs due to their non-tumorigenic and non-immunogenic properties, as well as their potential for rapid expansion as an off-the-shelf product.
- Other names
- wharton's jelly mesenchymal stromal cellsumbilical cord-derived mesenchymal stem cellsUC-MSCs
Beyond the preview
Go deeper on wharton's jelly-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on wharton's jelly-derived mesenchymal stem cells.